Byterna Therapeutics Secures Tens of Millions RMB in Angel Funding to Advance Circular mRNA In Vivo CAR-T Therapy

Recently, focusing on the loopZhuang RNAByterna Therapeutics: A New Drug Development Company for CAR-T Therapy（Byterna Therapeutics）It was announced that the company has completed an angel round of financing worth tens of millions of RMB. This round of financing was led by SunNovo, with participation from Beijing Fof Capital Co., Ltd. and other institutions. The proceeds will mainly be used to advance the preclinical development and investigator-initiated clinical trials (IIT) of circular mRNA in vivo CAR-T therapy.

Byterna Therapeutics is a cutting-edge technology company headquartered in Zhangjiang, Shanghai. Relying on leading circular RNA and in vivo CAR-T technology platforms, it is committed to developing innovative drugs that are "safe, effective, accessible, and affordable," promoting the clinical application of CAR-T therapy in major disease areas such as autoimmune diseases and malignant tumors, and addressing unmet medical needs.

Circular RNA, as a covalently closed and structurally stable RNA molecule, has been hailed by *Nature* magazine as "the next big thing in RNA therapeutics," showing broad prospects in fields such as vaccines, protein replacement, and cell and gene therapy (CGT). However, its industrialization faces technical bottlenecks in sequence design and chemical modification, especially since chemical modifications are difficult to make compatible with the circular structure, hindering drug development progress. Byterna Therapeutics, with its deep original expertise in AI-driven circular RNA sequence design and site-specific modification technology, is accelerating the construction of an intelligent technology platform, which is expected to be the first to overcome the globally common challenge of chemical modification.

By deeply integrating circular RNA technology with in vivo CAR-T therapy, Byterna Therapeutics is committed to building a "Best-in-Class" mRNA CAR-T in vivo therapy technology platform, accelerating the clinical translation of innovative therapies. Currently,Byterna TherapeuticsAccelerating the advancement of environmental equipmentRNA-based CAR-T Therapy In VivoThe research is expected to be the first to advance modified circular mRNA-based CAR-T therapy in vivo into clinical trials, becoming the world's first such therapy to enter clinical research.

Notably, in recent years, several large pharmaceutical companies have shown strong interest in "in vivo CAR-T cell therapy." This year has seen several major acquisition deals: AstraZeneca acquired EsoBiotech for $1 billion in March; AbbVie acquired Capstan Therapeutics for $2.1 billion in June; and Kite Pharma, a subsidiary of Gilead Sciences, acquired Interius BioTherapeutics for $350 million in August. With shifts in relevant policies and continuous technological breakthroughs, in vivo cell therapies, including in vivo CAR-T, are becoming the new frontier in the next generation of precision medicine competition.